<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629642</url>
  </required_header>
  <id_info>
    <org_study_id>905-EC-005</org_study_id>
    <secondary_id>2006-005523-42</secondary_id>
    <nct_id>NCT00629642</nct_id>
  </id_info>
  <brief_title>Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis</brief_title>
  <acronym>SONIC</acronym>
  <official_title>A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder
      symptoms due to spinal cord injury or multiple sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A clinical study to compare the efficacy and safety of solifenacin succinate in patients with
      neurogenic detrusor overactivity. In this randomized, double blind, double dummy study
      solifenacin will be compared to placebo and an active comparator, oxybutynin hydrochloride.
      Patients will be randomized to one of four treatment arms; solifenacin 10mg, solifenacin 5mg,
      placebo or oxybutynin 15mg. Patients will be assessed over a four week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2008</start_date>
  <completion_date type="Actual">January 28, 2011</completion_date>
  <primary_completion_date type="Actual">January 28, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in maximum cystometric capacity</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bladder volume at first involuntary contraction</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pressure at first leak</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in volume at first leak</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum detrusor pressure</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in micturition or catheterization frequency</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in incontinence episodes</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Neurogenic Bladder</condition>
  <condition>Spinal Cord Diseases</condition>
  <arm_group>
    <arm_group_label>I.Solifenacin succinate 10mg (2x5mg 1/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II.Solifenacin succinate 5mg (5mg 1/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III.Oxybutynin hydrochloride 15mg (5mg 3/day)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin Succinate</intervention_name>
    <description>Oral, 10mg</description>
    <arm_group_label>I.Solifenacin succinate 10mg (2x5mg 1/day)</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin Succinate</intervention_name>
    <description>Oral, 5mg</description>
    <arm_group_label>II.Solifenacin succinate 5mg (5mg 1/day)</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin Hydrochloride</intervention_name>
    <description>Oral, 15mg</description>
    <arm_group_label>III.Oxybutynin hydrochloride 15mg (5mg 3/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>IV. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent has been obtained

          -  Subjects with neurogenic detrusor overactivity due to:

               -  Multiple sclerosis(MS)(EDSS≤8) or

               -  Spinal cord injury(SCI)(partial or complete lesions)

          -  MS or SCI symptoms should be stable for &gt;= 6 months

          -  Neurogenic detrusor overactivity symptoms should be stable for &gt;= 6 months

          -  Subject is willing and able to perform clean, intermittent, catheterization, if
             required

          -  Subject is willing and able to take study medication in compliance with the protocol

        Exclusion Criteria:

          -  Subjects with neurogenic detrusor overactivity due to Parkinson's or cerebrovascular
             disease

          -  Subjects with Sjögren's Syndrome or any similar symptoms

          -  Subjects with evidence of a symptomatic urinary tract infection, chronic inflammation
             such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or
             previous or current malignant disease of the pelvic organs

          -  Subjects with stress incontinence or mixed incontinence where stress is the
             predominant factor as determined by the investigator

          -  Subjects with evidence of pressure sores &gt;= grade 2

          -  Subjects with a history of bladder sphincterotomy

          -  Subjects with known history of vesico-ureteral reflux without upper urinary tract
             infection

          -  Any clinically significant condition, which in the opinion of the investigator makes
             the subject unsuitable for the study or includes a history of acute urinary retention,
             severe gastrointestinal obstruction (including paralytic ileus or intestinal atony),
             severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis),
             myasthenia gravis, narrow angle glaucoma or shallow anterior chamber

          -  Subjects undergoing hemodialysis

          -  Subjects with severe hepatic impairment

          -  Concurrent use of drugs intended to treat symptoms of overactive bladder

          -  Use of antidepressants or muscle relaxants which have not been administered at a
             constant dose for &gt;= 3 months

          -  Use of non-drug treatment intended to treat overactive bladder symptoms including
             electrostimulation therapy, botulinum toxin and vanilloids therapy in the six months
             prior to the commencement of the study

          -  Use of permanent, indwelling catheters

          -  Known or suspected hypersensitivity to solifenacin succinate, oxybutynin
             hydrochloride, other anti cholinergics or lactose

          -  Concomitant use of a strong CYP3A4 inhibitor, e.g. ketoconazole

          -  Pregnant women, women who intend to become pregnant during the study, women of
             childbearing potential who are sexually active and practicing an unreliable method of
             birth control or women who will be lactating during the study. Reliable contraceptive
             methods are intra-uterine devices, contraceptive pills of combination type, hormonal
             implants and injectable contraceptives

          -  Participation in any clinical study within 30 days of randomization, or the limit set
             by national law, whichever is longer

          -  Employees of the Astellas Group, third parties associated with the study, or the study
             site

          -  Subjects with maximum bladder capacity &gt;= 400ml at visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Department of (Neuro) Urology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esneux</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fraiture-en-Condroz</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melsbroek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploemeur</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagenow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>190089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan de Alicante</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=213</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurogenic bladder</keyword>
  <keyword>Vesicare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

